Revenue has advanced only from $1.0M in 2024Q1 to $1.5M in 2026Q2 with COGS recorded at $0, leaving the reported 100% gross margin uninformative while operating losses widened to -$16.4M and the 2026Q2 net loss reached -$24.9M on roughly $8.5M of below-the-line charges.
Ocugen, Inc. (OCGN) annual income statement — 14-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 4.78M | 4.41M | 4.05M | 6.04M | 2.49M | 0 | 43K | 0 | 0 | 0 | 0 | 0 | 0 | 8K | 26K |
| Revenue Growth % | -11.01% | 8.83% | -32.82% | 142.6% | - | -100% | - | - | - | - | - | - | -100% | -69.23% | - |
| Cost of Goods Sold | 548K | 2.39M | 1.97M | 704K | 0 | 0 | 6.35M | 8.09M | 49.62K | 1.53M | 1.67M | 1.61M | 0 | 0 | 0 |
| COGS % of Revenue | - | 54.14% | 48.53% | 11.66% | - | - | 14776.74% | - | - | - | - | - | - | - | - |
| Gross Profit | 4.23M | 2.02M | 2.09M | 5.33M | 2.49M | 0 | -6.31M | -8.09M | -49.62K | -1.53M | -1.67M | -1.61M | 0 | 8K | 26K |
| Gross Margin % | 88.53% | 45.86% | 51.47% | 88.34% | 100% | - | -14676.74% | - | - | - | - | - | - | 100% | 100% |
| Gross Profit Growth % | - | -3.02% | -60.86% | 114.31% | - | 100% | 21.95% | -16194.86% | 96.77% | 8.31% | -3.66% | - | -100% | -69.23% | - |
| Operating Expenses | 73.26M | 64.94M | 56.84M | 70.86M | 91.56M | 58.03M | 14.97M | 6.08M | 25.84M | 24.95M | 30.11M | 31.51M | 32.6M | 16.79M | 14.99M |
| OpEx % of Revenue | - | 1471.56% | 1401.82% | 1174.01% | 3680.02% | - | 34823.26% | - | - | - | - | - | - | 209912.5% | 57669.23% |
| Selling, General & Admin | 28.7M | 27.58M | 26.69M | 31.99M | 35.4M | 22.92M | 7.97M | 6.08M | 10.2M | 9.38M | 8.53M | 8.27M | 6.75M | 4.85M | 3.05M |
| SG&A % of Revenue | - | 624.95% | 658.1% | 530.05% | 1422.83% | - | 18544.19% | - | - | - | - | - | - | 60587.5% | 11742.31% |
| Research & Development | 45.12M | 39.75M | 32.13M | 39.57M | 56.16M | 35.11M | 13.35M | 8.09M | 15.63M | 15.57M | 21.58M | 23.24M | 25.86M | 11.95M | 11.94M |
| R&D % of Revenue | - | 900.75% | 792.26% | 655.62% | 2257.19% | - | 31055.81% | - | - | - | - | - | - | 149325% | 45926.92% |
| Other Operating Expenses | -548K | -2.39M | -1.97M | -704K | 0 | 0 | -6.35M | -8.09M | 0 | -116K | -248K | -72K | 13K | -52K | -30K |
| Operating Income | -69.03M | -62.92M | -54.76M | -65.53M | -89.07M | -58.03M | -21.29M | -14.16M | -30.11M | -24.95M | -30.31M | -31.82M | -32.66M | -16.84M | -14.97M |
| Operating Margin % | -1444.47% | -1425.7% | -1350.36% | -1085.67% | -3580.02% | - | -49500% | - | - | - | - | - | - | -210562.5% | -57569.23% |
| Operating Income Growth % | - | -14.9% | 16.44% | 26.43% | -53.5% | -172.62% | -50.29% | 52.96% | -20.67% | 17.68% | 4.75% | 2.58% | -93.9% | -12.54% | - |
| EBITDA | -66.71M | -60.53M | -52.79M | -64.83M | -88.59M | -57.8M | -21.18M | -14.1M | -30.06M | -23.42M | -28.63M | -30.2M | -31.94M | -16.28M | -14.33M |
| EBITDA Margin % | -1395.89% | -1371.56% | -1301.82% | -1074.01% | -3560.73% | - | -49262.79% | - | - | - | - | - | - | -203487.5% | -55115.38% |
| EBITDA Growth % | -18.33% | -14.66% | 18.57% | 26.82% | -53.27% | -172.86% | -50.21% | 53.08% | -28.37% | 18.22% | 5.2% | 5.42% | -96.18% | -13.6% | - |
| D&A (Non-Cash Add-back) | 2.32M | 2.39M | 1.97M | 704K | 480K | 229K | 102K | 61K | 49.62K | 1.53M | 1.67M | 1.61M | 726K | 566K | 638K |
| EBIT | -71.86M | -62.66M | -54.05M | -63.08M | -86.8M | -58.34M | -14.29M | -14.16M | -14.47M | -26.41M | -13.05M | -31.89M | -22.64M | -16.79M | -14.97M |
| Net Interest Income | -9.55M | -4.27M | 1.3M | 2.5M | 1.4M | -79K | -719.9K | -1.77M | 0 | 0 | 0 | 0 | 0 | 0 | -798K |
| Interest Income | 1.32M | 922K | 1.3M | 2.5M | 1.4M | 0 | 1.06K | 1.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 10.22M | 5.19M | 0 | 0 | 0 | 79K | 720.96K | 1.77M | 163K | 134K | -60K | -133K | -151K | 0 | 798K |
| Other Income/Expense | 3.67M | -4.93M | 703K | 2.45M | 2.27M | -389K | -537K | -6.08M | 11.89M | -1.46M | 14.1M | -205K | 9.87M | -8.87M | -1.97M |
| Pretax Income | -65.36M | -67.85M | -54.05M | -63.08M | -86.8M | -58.42M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.93M |
| Pretax Margin % | -1367.61% | -1537.41% | -1333.02% | -1045.03% | -3488.91% | - | -50748.84% | - | - | - | - | - | - | -321400% | -65134.62% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -52K | 0 | 0 | -15.76M | -186K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.09% | 0% | 0% | 182.36% | 0.7% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -65.36M | -67.85M | -54.05M | -63.08M | -86.8M | -58.37M | -21.82M | -20.24M | -8.64M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.93M |
| Net Margin % | -1367.61% | -1537.41% | -1333.02% | -1045.03% | -3488.91% | - | -50748.84% | - | - | - | - | - | - | -321400% | -65134.62% |
| Net Income Growth % | -2.09% | -25.52% | 14.31% | 27.33% | -48.73% | -167.46% | -7.8% | -134.21% | 67.28% | -62.97% | 49.39% | -40.5% | 11.35% | -51.83% | - |
| Net Income (Continuing) | -65.36M | -67.85M | -54.05M | -63.08M | -86.8M | -58.37M | -21.82M | -20.24M | -18.22M | -26.41M | -16.21M | -32.02M | -22.79M | -25.71M | -16.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.19 | -0.23 | -0.20 | -0.26 | -0.40 | -0.30 | -0.31 | -1.53 | -13.98 | -69.91 | -67.58 | -145.22 | -891.47 | -120.93 | -79.65 |
| EPS Growth % | 9.09% | -15% | 23.08% | 35% | -33.33% | 3.23% | 79.74% | 89.06% | 80% | -3.45% | 53.46% | 83.71% | -637.18% | -51.83% | - |
| EPS (Basic) | - | -0.23 | -0.20 | -0.26 | -0.40 | -0.30 | -0.31 | -1.53 | -13.98 | -69.91 | -68.21 | -145.22 | -891.47 | -120.93 | -79.65 |
| Diluted Shares Outstanding | 339.21M | 300.17M | 271M | 244.33M | 214.6M | 195.01M | 112.24M | 13.89M | 618.18K | 377.84K | 239.82K | 220.52K | 25.57K | 212.62K | 212.62K |
| Basic Shares Outstanding | 339.21M | 300.17M | 271M | 244.33M | 214.6M | 195.01M | 112.24M | 13.89M | 618.18K | 377.83K | 237.62K | 220.52K | 25.57K | 212.62K | 212.62K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying OCGN stock.
For fiscal year 2025, Ocugen, Inc. (OCGN) reported total revenue of $4.4M. This represents a 16873.1% increase compared to $0.0M in 2012.
Ocugen, Inc. (OCGN) reported a net loss of $67.8M for the fiscal year ending 2025.
Ocugen, Inc. (OCGN) reported an operating income of $-62.9M, resulting in an operating profit margin of -1425.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Ocugen, Inc. (OCGN) generated $2.0M in gross profit for the year, representing a gross profit margin of 45.9%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
R&D Outpacing Revenue Growth
Metrics are mathematically derived from official filings.
Flat Revenue Amid Volatile Quarters
As reported in Ocugen's quarterly statements, revenue has moved only from $1.0M in 2024Q1 to $1.5M in 2026Q2, a roughly 50% gain spread over ten quarters with swings as wide as -125.3% and +135.3% quarter-over-quarter.
The last three quarters ($1.8M, -$193K, $1.5M) suggest recognition is lumpy rather than tied to a growing commercial base, so the headline growth rates appear to measure timing, not demand. Because COGS is recorded at zero, there is no volume-versus-price decomposition available; revenue adds almost nothing to a cost base near $18M per quarter. Investors should treat the 8.4% and 3.5% recent growth prints as noise around a flat top line until a durable revenue driver is evidenced.
Zero-COGS Model Distorts Margin Read
According to Ocugen's reported figures, gross margin has printed 100.0% in every quarter because COGS is recorded at $0, leaving gross profit equal to revenue and rendering the metric uninformative about pricing power or manufacturing efficiency.
At $1.5M, gross profit covers only about 8% of the $17.9M in combined R&D and SG&A for 2026Q2, so the structural issue is scale, not margin compression. Peer comparables such as BEAM at 84.0% and NTLA at 76.5% achieve similar margin optics on 27x-93x Ocugen's revenue, underscoring that Ocugen's 100% figure reflects an absence of commercial activity rather than competitive positioning. The 2025Q4 line showing -$193K gross profit alongside a 100.0% margin and a positive 88.1% operating margin is internally inconsistent and warrants further investigation.
Losses Deepen Despite Overhead Triage
As disclosed in Ocugen's income statements, the operating loss widened from -$12.2M in 2024Q1 to -$16.4M in 2026Q2 as operating expenses climbed from $13.2M to $17.9M, while revenue contributed only $1.5M of offset, roughly 12 times the top line.
There is no observable operating leverage because incremental gross profit is immaterial; each additional dollar of R&D or SG&A falls straight through to operating income. SG&A has oscillated between $6.1M and $8.2M without a clear trend, which may indicate project-timed or collaboration-linked spending rather than a controlled overhead trajectory. The operating margin deteriorated from -12.0% to -11.1% over the period only because revenue ticked up slightly, not because costs were absorbed.
Below-Line Items Inflate Q2 Loss
In 2026Q2, Ocugen's net loss of -$24.9M exceeded its -$16.4M operating loss by roughly $8.5M, the widest gap in the ten-quarter series, implying non-operating charges that warrant further investigation before treating the -$0.07 quarterly EPS as a run-rate.
Stock-based compensation of $1.8M-$3.4M per quarter is a recurring non-cash drag that appears to be growing faster than revenue, peaking at $3.4M in 2026Q1 against $1.5M of sales. Dilution is already visible in the EPS path, which moved from -$0.04 in 2024Q2 to -$0.07 in 2026Q2 even as quarterly losses expanded, so per-share deterioration outpaces the absolute loss growth on certain periods. Tax and other non-operating detail is not disclosed in the supplied data, limiting how far the quality of the -$19.2M and -$24.9M net prints can be decomposed.
What Could Invalidate the Base Case
A short-seller would note that Ocugen's -$24.9M quarterly net loss is more than 16 times its $1.5M revenue while R&D has advanced to $10.7M without any corresponding revenue inflection, suggesting the cost base may be outrunning any visible return.
R&D stepped up from $6.8M in 2024Q1 to $11.3M in 2026Q1, a 66% increase that produced no durable uplift in the revenue line, which questions whether program spending is converting into monetizable milestones. The widening gap between operating loss and net loss, plus rising SBC, hints that reported results may be increasingly influenced by items outside core operations, an area a bear would probe first. Cash runway and balance-sheet capacity are not provided in the supplied data, so the ability to fund this trajectory remains unverified and is the key variable investors should monitor.